All In Biotech

NDA 012827 · Casper Pharma LLC

Robinul Forte

Glycopyrrolate · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Sep 27, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1961

Aug 11, 1961

Approved uses

1

Original approval plus efficacy supplements

Registered trials

230

60 Phase 3, 12 recruiting

FAERS reports

5,527

4,660 serious, 660 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 17, 2026.

Glycopyrrolate are indicated in adults to reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer. Limitations of Use Glycopyrrolate are not indicated as monotherapy for the treatment of peptic ulcer because effectiveness in peptic ulcer healing has not been established. Glycopyrrolate are anticholinergics indicated in adults to reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer. (1) Limitations of Use: Not indicated as monotherapy for the treatment of peptic ulcer because effectiveness in peptic ulcer healing has not been established. (1)

Mechanism: Glycopyrrolate, an anticholinergic (antimuscarinic) agent, inhibits the action of acetylcholine on parietal cells in the stomach and decreases the volume and acidity of gastric secretions.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 11, 1961 Original approval · Type 1 - New Molecular Entity
2 products under this application
  • ROBINUL FORTE · GLYCOPYRROLATE 2MG · TABLET, ORAL · Prescription · TE AA
  • ROBINUL · GLYCOPYRROLATE 1MG · TABLET, ORAL · Prescription · TE AA

Clinical trials

Interventional ClinicalTrials.gov studies with "Glycopyrrolate" as an intervention, any sponsor and status, largest first.

All 230 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea1,054
  • asthma852
  • wheezing719
  • cough669
  • pneumonia576
  • drug ineffective444
  • off label use374
  • fatigue373
  • malaise365
  • chronic obstructive pulmonary disease361
  • productive cough350
  • chest discomfort337

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200412
200514
200616
200730
200829
200946
201062
201174
201288
201370
2014125
2015134
2016216
2017428
2018291
2019315
2020281
2021444
2022619
2023568
2024605
2025669
2026390

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 443 on PubMed

Sponsor: Casper Pharma LLC · Also marketed as Robinul

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.